Citadel Advisors
BIVV

Citadel Advisors’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Citadel Advisors’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-25,300
Closed -$1.36M – 9164
2017
Q4 		$1.36M Buy
25,300
+9,300
+58% +$509K ﹤0.01% 4184
2017
Q3 		$913K Buy
16,000
+1,500
+10% +$87.9K ﹤0.01% 4445
2017
Q2 		$872K Buy
+14,500
New +$826K ﹤0.01% 4282

Other funds holding BIVV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
ACS
Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Citadel Advisors's BIVV Position: Q1 2018 in Review

Citadel Advisors sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 36,907 shares — an estimated $1.99M sold.

Citadel Advisors first reported a position in BIVV in Q2 2017 and held it in 3 quarters. The position peaked at $7.87M in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

  • Citadel Advisors reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Citadel Advisors sold 36,907 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $1.99M.
  • Citadel Advisors first reported a position in Bioverativ Inc. Common Stock in Q2 2017 and held it in 3 quarters.
  • Citadel Advisors's Bioverativ Inc. Common Stock position peaked at $7.87M in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Citadel Advisors's 13F filing for Q1 2018, filed 11 May 2018.